This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Corneal Disorders  • Drug Therapy  • Alert me on articles by topic

John J. DeStafeno, MD; Terry Kim, MD

Arch Ophthalmol. 2007;125(6):834-836.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Angiogenesis has been defined as the formation of new blood vessels from preexisting vascular structures. Corneal neovascularization (NV) occurs when the balance between angiogenic and antiangiogenic factors shifts toward angiogenic factors.¹ Vascular endothelial growth factor (VEGF) has been found to be a significant angiogenic factor in corneal NV in human and animal models.² Therapy specifically aimed at VEGF may suppress corneal NV and increase the chance of transplant survival. We report the use of a topical formulation of bevacizumab, a humanized monoclonal antibody to VEGF, in 2 patients with significant corneal NV.

Report of Cases

Case 1

A 20-year-old man was seen at Duke University Eye Center approximately 1 year after ocular trauma to the left eye from carbonized debris expelled from a high-pressure hose. Examination revealed a best-corrected visual acuity of 20/20 OD and counting fingers OS. Slitlamp examination in the left eye revealed extensive residual debris . . . [Full Text of this Article]

Case 2

Comment

AUTHOR INFORMATION